<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01518595</url>
  </required_header>
  <id_info>
    <org_study_id>1-Fuhrmann</org_study_id>
    <nct_id>NCT01518595</nct_id>
  </id_info>
  <brief_title>Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis</brief_title>
  <official_title>Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis - a Prospective Double Blind Randomized Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      The most common observed cause of gas exchange abnormalities and hypoxemia in cirrhosis is
      the hepatopulmonary syndrome (HPS) with a reported prevalence of 20-47% in patients with
      hepatic impairment and cirrhosis. HPS is by far the most frequent respiratory complication of
      cirrhosis. It is a progressive disease leading to significantly increased mortality. Up to
      date, the only therapeutic option is liver transplantation. The study hypothesis is that
      administration of bosentan in patients with liver cirrhosis suffering from hepatopulmonary
      syndrome improves gas exchange. 18 patients with liver cirrhosis fulfilling criteria of HPS
      according to the ERS task force criteria will be included in this block randomized,
      double-blind, placebo controlled study (12 patients will be treated with bosentan, 6 with
      placebo). Patients will receive bosentan 62,5mg b.i.d. for 4 weeks and 125 mg b.i.d. for 8
      weeks or placebo. The duration of the treatment phase of the study is 12 weeks. The primary
      endpoint is the alteration of gas exchange after 3 months of therapy. The expected duration
      of the study is 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    too slow patient recruitment
  </why_stopped>
  <start_date>October 2011</start_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>alveolar-arterial oxygen gradient in mmHg</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>presence of HPS</measure>
    <time_frame>3 months</time_frame>
    <description>assessment via contrast enhanced transthoracic echocardiography and pulmonary function testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minutes walking distance in m</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO functional class</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>we will us the CAT-questionaire for QoL assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aminotransferase level (ASAT, ALAT)</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of the aminotransferase levels in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exhanled nitric oxide in parts per billion</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatic venous pressure gradient (HVPG) in mmHg</measure>
    <time_frame>3 months</time_frame>
    <description>HVPG will be assessed after inclusion in the study and after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary hemodynamics</measure>
    <time_frame>3 months</time_frame>
    <description>pulmonary hemodynamics will be assessed after inclusion and after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean arterial blood pressue in mmHg</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>partial pressure of arterial oxygen in mmHg</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Hepatopulmonary Syndrome</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo tablets twice daily for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bosentan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pts. will receive bosentan for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>pts. will receive bosentan for 3 months</description>
    <arm_group_label>bosentan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>pts. will receive placebo for 3 months</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of HPS

          -  Age â‰¥ 18 years

        Exclusion Criteria:

          -  Intracardiac shunting

          -  Pregnancy

          -  Known hypersensitivity to bosentan

          -  Use of glyburide

          -  Use of cyclosporin A

          -  Elevation of aminotransferase level of &gt; 3 times the upper limit of normal

          -  Use of rifampicin

          -  Females of childbearing potential without use of adequate contraception

          -  Systolic blood pressure &lt; 85 mmHg

          -  Clinical relevant anemia

          -  HIV-infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valentin H Fuhrmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Vienna, Dpt. of Internal Medicine 3, Div. of Gastroenterology and Hepatology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2011</study_first_submitted>
  <study_first_submitted_qc>January 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Valentin Fuhrmann</investigator_full_name>
    <investigator_title>MD, Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatopulmonary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

